B
Bio-Rad Laboratories, Inc.
BIO · Healthcare
Q4 FY2025
Earning ended Dec 31, 2025Report generated Mar 15, 2026
Sticky Customers, Stagnant Returns, and a Stake That Runs the Show
Most investors are debating whether Life Science tools are recovering — the real question is whether Bio-Rad's operating business has ever earned its cost of capital, because the answer appears to be no, and the Sartorius stake has been obscuring that structural reality for years.
Flowly Score
Apr 16 Close
-35%$291.09
Fair Value
$190.00
39
Below Averageat $291.09
Business Strength5/10
The razor-and-blades installed base creates genuine customer retention, particularly in accredited clinical labs where switching risks accreditation — but switching costs that prevent defection are not the same as pricing power that earns excess returns, and ROIC has sat below the cost of capital through boom and bust alike. Family governance insulates management from accountability on the most consequential strategic question they face: what to do with a passive stake that has at times dwarfed the operating business in reported value.
Financial Resilience6/10
Strip out the Sartorius noise and you find an operating business in the middle of a genuine FCF inflection — free cash flow compounding meaningfully upward each year, with the latest period representing a step-change in conversion quality. The balance sheet carries real debt against modest operating earnings, but the cash generation trend is moving in the right direction and management has demonstrated willingness to use buybacks opportunistically rather than defensively.
Growth & Trajectory4/10
The destocking narrative is finally aging out, but just as that tailwind materializes, a fresh structural headwind has arrived in process chromatography — a mid-teens decline driven by regulatory changes in vaccines and customers optimizing production efficiency, with recovery pushed to 2027 at the earliest. Guiding to essentially flat currency-neutral growth in 2026 with a Q1 decline is not a recovery story; it's a business still searching for its next durable growth vector.
Valuation3/10at $262.80
The P/E looks superficially cheap, but it's built on a year where Sartorius appreciation inflated reported earnings — the operating business on a normalized FCF basis looks stretched relative to a company with sub-cost-of-capital returns and sub-2% organic growth guidance. Sum-of-parts provides a genuine floor that pure DCF misses, but that floor depends entirely on Sartorius recovering, which is itself a bet on biopharma manufacturing capex normalizing — a second-order dependency that the current price doesn't adequately compensate for.
Risk4/10
The most underappreciated risk isn't cyclical — it's structural displacement in China, where domestically produced instruments are systematically taking share in a market that was supposed to be a growth engine, and that trend doesn't reverse as local alternatives improve. Layer on top: governance architecture with no minority shareholder recourse, a passive mega-stake whose volatility dominates reported results, and a process chromatography business that just delivered a surprise mid-teens decline — these aren't abstract categories, they're concrete situations already happening.
Bio-Rad sits at a deceptive crossroads: the headline P/E looks cheap, FCF conversion is the best it's been in years, and the destocking narrative is finally running out of road. But cheapness on earnings that are 90% driven by a passive equity stake isn't cheapness — it's a mirage. The operating business, evaluated on its own merits, has never cleared the cost of capital, and the current valuation on operating cash flows alone implies meaningful overvaluation. The sum-of-parts case — crediting the Sartorius position at fair value — provides genuine support, but that support is contingent on a separate company's recovery, not on anything Bio-Rad's management controls. The trajectory story is complicated by a fresh surprise: just as the multi-year COVID destocking hangover was clearing, process chromatography delivered a mid-teens decline driven by external regulatory changes and customer efficiency gains that management didn't see coming until late 2024. That's a meaningful signal about visibility quality in what was supposed to be a durable recurring-revenue niche. Clinical Diagnostics is stable but slow, guided to grow barely faster than inflation. The ddPCR platform is genuinely encouraging — mid-single-digit growth with an installed base skewing toward higher-margin consumables — but it's not yet large enough to move the revenue needle at the total company level. The single biggest risk is the Sartorius dependency creating a false sense of value while obscuring an operating business that hasn't compounded well. If biopharma manufacturing capex normalizes and Sartorius recovers, the sum-of-parts math closes and the stock looks reasonable. If biopharma spending stays compressed — or if the next Sartorius leg down arrives before the operating business finds its growth engine — the pure operating DCF reasserts itself as the dominant valuation frame, and that frame suggests the current price is pricing in a recovery the business hasn't yet earned.